Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol

Journal of Immunological Methods

Volumn 381, Issue 1-2, 2012, Pages 1-8

  Herbert, Megan K ^a   Kuiperij, H Bea ^a   Verbeek, Marcel M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Confounding factors; CSF; Glutamine synthetase; Myelin basic protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; EPITOPE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE AMMONIA LIGASE; MYELIN BASIC PROTEIN; TAU PROTEIN;

ACIDIFICATION FOLLOWED BY NEUTRALISATION; ANTIGEN BINDING; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; HUMAN; PH; PREMEDICATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; STANDARDIZATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CEREBROSPINAL FLUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE-AMMONIA LIGASE; HUMANS; HYDROGEN-ION CONCENTRATION; MYELIN BASIC PROTEINS; NEURODEGENERATIVE DISEASES; NEUTRALIZATION TESTS; PHOSPHORYLATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84861571910     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.04.001     Document Type: Article

References (38)

1. Abdo W.F., De Jong D., Hendriks J.C., Horstink M.W., Kremer B.P., Bloem B.R., Verbeek M.M. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov. Disord. 2004, 19:571.
2. Belogurov A.A., Kurkova I.N., Friboulet A., Thomas D., Misikov V.K., Zakharova M.Y., Suchkov S.V., Kotov S.V., Alehin A.I., Avalle B., Souslova E.A., Morse H.C., Gabibov A.G., Ponomarenko N.A. Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J. Immunol. 2008, 180:1258.
3. Bibl M., Esselmann H., Otto M., Lewczuk P., Cepek L., Ruther E., Kornhuber J., Wiltfang J. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 2004, 25:2912.
4. Bjerke M., Portelius E., Minthon L., Wallin A., Anckarsater H., Anckarsater R., Andreasen N., Zetterberg H., Andreasson U., Blennow K. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int. J. Alzheimer's Dis. 2010, 2010:2010.
5. Boenisch T. Heat-induced antigen retrieval: what are we retrieving?. J. Histochem. Cytochem. 2006, 54:961. [Review] [8 refs].
6. Boros S., Kamps B., Wunderink L., de Bruijn W., de Jong W.W., Boelens W.C. Transglutaminase catalyzes differential crosslinking of small heat shock proteins and amyloid-β. FEBS Lett. 2004, 576:57.
7. Douglas M.R., Daniel M., Lagord C., Akinwunmi J., Jackowski A., Cooper C., Berry M., Logan A. High CSF transforming growth factor beta levels after subarachnoid haemorrhage: association with chronic communicating hydrocephalus. J. Neurol. Neurosurg. Psychiatry 2009, 80:545.
8. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734. [Review] [143 refs].
9. Goldblatt D., van Etten L., van Milligen F.J., Aalberse R.C., Turner M.W. The role of pH in modified ELISA procedures used for the estimation of functional antibody affinity. J. Immunol. Methods 1993, 166:281.
10. Groome N.P., Dawkes A., Gales M., Hruby S., Alvord E.C. Region-specific immunoassays for human myelin basic protein. J. Neuroimmunol. 1986, 12:253.
11. Grundström E., Lindholm D., Johansson A., Blennow K., Askmark H. GDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis. Neuroreport 2000, 11:1781.
12. Hnasko R., Lin A., McGarvey J.A., Stanker L.H. A rapid method to improve protein detection by indirect ELISA. Biochem. Biophys. Res. Commun. 2011, 410:726.
13. Hühmer A.F., Biringer R.G., Amato H., Fonteh A.N., Harrington M.G. Protein analysis in human cerebrospinal fluid: physiological aspects, current progress and future challenges. Dis. Markers 2006, 22:3. [Review] [131 refs].
14. Iłzecka J. Decreased cerebrospinal fluid cGMP levels in patients with amyotrophic lateral sclerosis. J. Neural Transm. 2004, 111:167.
15. Ittner L.M., Götz J. Amyloid-β and tau - a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12:67.
16. Julian E., Cama M., Martinez P., Luquin M. An ELISA for five glycolipids from the cell wall of Mycobacterium tuberculosis: Tween 20 interference in the assay. J. Immunol. Methods 2001, 251:21.
17. Krajewski W.W., Collins R., Holmberg-Schiavone L., Jones T.A., Karlberg T., Mowbray S.L. Crystal structures of mammalian glutamine synthetases illustrate substrate-induced conformational changes and provide opportunities for drug and herbicide design. J. Mol. Biol. 2008, 375:217-228.
18. Lamers K.J., de Reus H.P., Jongen P.J. Myelin basic protein in CSF as indicator of disease activity in multiple sclerosis. Mult. Scler. 1998, 4:124.
19. Lechtzier V., Hutoran M., Levy T., Kotler M., Brenner T., Steinitz M. Sodium dodecyl sulphate-treated proteins as ligands in ELISA. J. Immunol. Methods 2002, 270:19.
20. Li Q., Gordon M., Cao C., Ugen K.E., Morgan D. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci. 2007, 8:22.
21. Lyons R.M., Keski-Oja J., Moses H.L. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J. Cell Biol. 1988, 106:1659.
22. Macklin W.B., Lees M.B., Cohen S.R., Ayella S.B. Hydrophobic compounds interfere in radioimmunoassay for basic protein in myelin. Clin. Chem. 1981, 27:742.
23. Mastroianni C.M., Liuzzi G.M., Vullo V., Jirillo E., Delia S., Riccio P. Detection of cerebrospinal fluid antibodies against myelin basic protein in patients with AIDS dementia complex. Mol. Chem. Neuropathol. 1991, 14:227.
24. Mattsson N. CSF biomarkers in neurodegenerative diseases. Clin. Chem. Lab. Med. 2011, 49:345.
25. Mattsson N., Blennow K., Zetterberg H. CSF biomarkers: pinpointing Alzheimer pathogenesis. Ann. N. Y. Acad. Sci. 2009, 1180:28. [Review] [74 refs].
26. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011, 7:263.
27. Okragly A.J., Haak-Frendscho M. An acid-treatment method for the enhanced detection of GDNF in biological samples. Exp. Neurol. 1997, 145:t-6.
28. Olabarria M., Noristani H., Verkhratsky A., Rodriguez J. Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer's disease mouse model: mechanism for deficient glutamatergic transmission?. Mol. Neurodegener. 2011, 6:55.
29. Olsson B., Zetterberg H., Hampel H., Blennow K. Biomarker-based dissection of neurodegenerative diseases. Prog. Neurobiol. 2011, 95:520.
30. Prince G., Delaere P., Fages C., Lefrançois T., Touret M., Salanon M., Tardy M. Glutamine synthetase (GS) expression is reduced in senile dementia of the Alzheimer type. Neurochem. Res. 1995, 20:859.
31. Shaw G., Hawkins J. Identification of spinal cord polypeptides related to glial fibrillary acidic protein (GFAP). Neuroreport 1992, 3:461.
32. Teunissen C.E., Verwey N.A., Kester M.I., van U.K., Blankenstein M.A. Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid beta((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop. Int. J. Alzheimer's Dis. 2010, 6. 10.4061/2010/635053.
33. Tumani H., Shen G.Q., Peter J.B. Purification and immunocharacterization of human brain glutamine synthetase and its detection in cerebrospinal fluid and serum by a sandwich enzyme immunoassay. J. Immunol. Methods 1995, 188:155.
34. Tumani H., Shen G., Peter J.B., Bruck W. Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer disease?. Arch. Neurol. 1999, 56:1241.
35. van Geel W.J., de Reus H.P., Nijzing H., Verbeek M.M., Vos P.E., Lamers K.J. Measurement of glial fibrillary acidic protein in blood: an analytical method. Clin. Chim. Acta 2002, 326:151.
36. Verbeek M.M., De Jong D., Kremer H.P.H. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann. Clin. Biochem. 2003, 40:25.
37. Warren K.G., Catz I. A correlation between cerebrospinal fluid myelin basic protein and anti-myelin basic protein in multiple sclerosis patients. Ann. Neurol. 1987, 21:183.
38. Zettler C., Bridges D.C., Zhou X.F., Rush R.A. Detection of increased tissue concentrations of nerve growth factor with an improved extraction procedure. J. Neurosci. Res. 1996, 46:581.